Neuronetics (FRA:NRC) Valuation Rank


FRA:NRC Neuronetics Inc FRA:NRC
57 GF Score
Price €1.17
GF Value €1.61
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Neuronetics Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Neuronetics Valuation Rank Related Terms

FRA:NRC
57GF Score
Neuronetics Inc FRA:NRC
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Neuronetics (FRA:NRC) Overvalued in 2026?

Based on GuruFocus' analysis, Neuronetics stock appears to be undervalued. The current stock price of €1.17 is trading 27.6% below its estimated GF Value™ of €1.61. GuruFocus considers Neuronetics to be Modestly Undervalued.

Key valuation signals for FRA:NRC:

  • Valuation Rank:
  • GF Value™: €1.61 vs. price of €1.17 (27.6% below fair value)
  • GF Score™: 57/100 with 4 warning signs

No single metric tells the full story. See the FRA:NRC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Neuronetics Business Description

Other Exchanges STIM:USA
Address 3222 Phoenixville Pike, Malvern, PA, USA, 19355
Neuronetics Inc a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advance Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advance Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address the existing treatment options. The company operates in two segments: medical devices and clinic services.
57GF Score

Get the complete analysis for FRA:NRC

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.17
Price
€1.61
GF Value